# Intactis Bio **Type:** venture **Status:** Draft **Confidence:** Low **Focus:** biological computing, hybrid biosilicon AI, neuromorphic compute, deep tech **Stage:** Pre-seed; biocomputation alpha platform live (2025); $250K Nucleus Fund + $100K RPV **Location:** Salt Lake City, UT (resident at Altitude Lab) **Updated:** 2026-05-09 **Needs-reviewed:** 2026-05-09 **Hero:** /img/heroes/front/intactis-bio-1600.webp **Hero caption:** *AI-generated illustration of a microfluidic biochip cradling living neural tissue, wired to a silicon microelectrode array — temporary synthetic placeholder, not a photograph of the actual Intactis Bio device. Replace with a license-cleared Intactis Bio image before any production use.* **Pull:** *3D-printed living neurons, wired to silicon, asked to do matrix math.* **Relates:** cites [PR Newswire — Lab-Grown Neurons "Hello World" and $250K Raise](intactis-bio-prnewswire.md) ## Summary Intactis Bio is a Salt Lake City company, founded in 2024 by Daniel Rodriguez-Granrose, building hybrid biosilicon computers: 3D-printed living neural tissue interfaced with custom silicon hardware through microelectrode arrays. The thesis is that living neurons — the existence proof for dense, ~20W adaptive computation — could become a useful inference substrate for AI workloads where conventional silicon is hitting power, heat, and capital walls. The company is a resident of Altitude Lab (a Recursion Pharmaceuticals incubator) and has raised pre-seed capital from Nucleus Fund ($250K), RPV ($100K of a $300K commitment), plus support from a SHIFT grant and an Altitude Lab Trail Angel Grant. For the Great Work Utah wiki, Intactis is the strangest entry on this issue's cover by design: pre-revenue, pre-validation, but exactly the kind of frontier compute paradigm that would be irresponsible to leave out of a guide that's serious about what is being attempted in Utah. ## Impact The honest assessment is that Intactis has not yet produced impact in the world. What it has produced are early signals: in March 2026 the company announced a lab demonstration in which iPSC-derived neurons coupled to custom silicon hardware produced task-distinct activity patterns for arithmetic and language inputs, alongside a "biocomputation alpha" letting customers test AI/ML workflows against living-neuron biochips with silicon baselines. The world-scale version of impact is not "brains in jars replace GPUs." It is a narrow but useful biological accelerator for tasks where adaptation, pattern separation, or energy efficiency matters more than deterministic digital logic. That bet remains unproven. Cortical Labs (Melbourne, with peer-reviewed DishBrain results), FinalSpark (Switzerland, with a commercial neuromorphic cloud), and Organic Robotics (Cornell) are all further along on adjacent paradigms. ## What They Are Building The product surface is an alpha biocomputation platform: customers submit silicon-trained models, Intactis converts them to biological inference format and runs them on living neural biochips, returning results alongside a silicon baseline. Phase 2 (planned 2027) expands to in-tissue training. The hard problems are exactly where you'd expect: keeping the tissue alive and consistent for commercial use, establishing reliable input/output protocols, and demonstrating that biological inference actually beats silicon on a real benchmark rather than a toy task. For talent, this is a founding-team-plus-a-few-researchers environment: high leverage for someone with the right mix of neuroscience, bioelectronic engineering, wetlab automation, and ML; very high ambiguity, low career safety. ## What They Need Now Likely needs include neuroscientists comfortable with iPSC and 3D-printed tissue work, bioelectronic engineers who can iterate on the electrode and packaging interface, ML researchers willing to work on benchmark design for non-silicon substrates, lab automation engineers, and anyone who can help close the gap between "interesting demonstration" and "reproducible, fairly-benchmarked product." ## Who Could Help Useful helpers include neural-engineering advisors, IP counsel familiar with the bioelectronics patent landscape, deep-tech investors comfortable with long timelines and binary outcomes, regulatory and bioethics advisors, and anyone with experience translating university tissue-culture work into manufacturable products. The Altitude Lab and Nucleus Institute communities are particularly close-by. ## Utah Context Intactis is a resident of [Altitude Lab](https://altitudelab.org/), the Recursion-spun incubator in Salt Lake City, and is technology and research spun out of the University of Utah. Utah's existing strengths around Recursion-style high-throughput biology, the U of U's biomedical engineering ecosystem, and the Wasatch Front's growing AI infrastructure make this a more credible place to attempt biohybrid compute than the company's sub-million-dollar capital base would suggest in isolation. ## Evidence - [Intactis Bio website](https://www.intactis.bio/) - [Intactis Bio biocomputation alpha](https://www.intactis.bio/biocomputation-alpha) - [PR Newswire: lab-grown neurons say "Hello, World"](https://www.prnewswire.com/news-releases/lab-grown-neurons-say-hello-world-and-perform-matrix-math-on-automated-platform-intactis-bio-corp-raises-250k-from-nucleus-fund-302724652.html) — [source record](intactis-bio-prnewswire.md) - [TechBuzz News: Intactis Bio and living neural tissue](https://www.techbuzznews.com/intactis-bio-pioneering-energy-efficient-ai-with-living-neural-tissue/) - [Utah Business: Utah AI momentum and Intactis Bio](https://www.utahbusiness.com/deal-dispatch/2026/03/03/deal-dispatch-utah-ai-momentum-deep-tech-jump-intactis-bio-nucleus-fund/) ## Open Questions - The strongest technical claims are currently company-reported; independent peer-reviewed replication is essential before any of this can be taken at face value. - $350K in total capital is pre-proof-of-concept territory; the company will need much more funding to survive to Phase 2. - The current hero is an AI-generated illustration produced by the Cursor agent (Claude Opus 4.7), not a photograph of the actual Intactis biochip. The PNG file carries explicit AI-generation metadata (Software, Source = AI-generated, DigitalSourceType = TrainedAlgorithmicMedia, and a prominent Comment chunk). A license-clean photograph of the actual Intactis biochip and lab — or an approved company image — would be a meaningful upgrade.